Patient experience is far more than a performance metric. It is a structural factor that shapes enrollment, retention, and the long-term quality of clinical res...
Continue reading
Sano raises $11 million in Series A funding round led by MMC Ventures New funding will support the team to grow and further its mission to accelerate personalis...
Continue reading
Virtual and decentralized trial models have moved from emergency workaround to strategic default for many precision medicine programs. This article examines whe...
Continue reading
Sano Genetics supports personalised medicine research by increasing participation in clinical trials and guiding patients through the process Half of clinical t...
Continue reading
If you missed our webinar, you can catch up on an exciting discussion about the future of precision medicine research in multiple sclerosis here on our blog.
Continue reading
Genetic testing has expanded significantly, both in clinical contexts and beyond. Understanding the distinctions between testing modalities—genotyping, targeted...
Continue reading
Advances in large-scale genome sequencing, data storage, and analysis are accelerating the development of precision medicine across a growing number of therapeu...
Continue reading
Polygenic risk scores enable clinicians and researchers to stratify patient populations by genetic risk, informing decisions on screening schedules, therapeutic...
Continue reading
Clinical trials increasingly depend on genomic data to identify the right patients, reduce variability in treatment response, and accelerate the path to approva...
Continue reading